Navigation Links
Stereotaxis Awarded Exclusive Contract by Novation for Robotic Interventional Technology
Date:9/10/2009

ST. LOUIS, Sept. 10 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced that Novation, the leading health care supply contracting company, will add Stereotaxis' Niobe(R) Remote Magnetic Navigation and Odyssey(TM) systems to its capital products contract portfolio. This is an exclusive agreement; Stereotaxis' Niobe System will be the only robotic interventional technology among Novation's capital products offerings. This agreement is effective immediately.

Based in Irving, Texas, Novation serves more than 2,500 hospitals in VHA Inc., and University HealthSystem Consortium (UHC), two national health care alliances, and nearly 950 hospital members of Provista, LLC, one of the nation's largest supply chain improvement companies. In 2008, these members used Novation contracts to purchase nearly $35 billion in supplies and services. Stereotaxis' contract with Novation enhances its opportunities to sell its capital products to the hospitals served by Novation, and eases contract negotiations between Stereotaxis and Novation's member hospitals.

"Novation prides itself in developing relationships with cutting-edge companies once they have established market leadership in a particular segment," said Michael Ainsworth, Director of Cardiovascular Contracting at Novation. "With the Niobe and Odyssey systems in our capital products portfolio, these breakthrough technologies will be more accessible to our membership. Capital equipment is among our specialties, representing up to 23 percent of our annual volume. We expect great things from our contract with Stereotaxis."

"We expect this exclusive contract to significantly enhance our U.S. growth opportunities," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "Stereotaxis' Niobe System is creating a new standard for the treatment of cardiac arrhythmias and the performance of other interventional applications. Our Odyssey System is set to fundamentally alter how procedure data is stored and best practices are shared between clinicians, which can ultimately improve patient care. Our contract with Novation should help pave the way for many institutions to add these game-changing technologies in their cath labs."

About the Niobe(R) and Odyssey(TM) Systems

The Niobe Remote Magnetic Navigation System is installed in approximately 120 hospitals worldwide. It allows physicians to treat cardiovascular disorders with a great degree of efficiency, safety, and precision by controlling the magnetic field around the patient and directing magnetically enabled devices through the patient's anatomy. Sophisticated software integrates medical images to create virtual reconstructions of the patient's blood vessels and heart to help accurately guide the devices to the diseased tissue and deliver therapy while minimizing the need for x-ray exposure.

Overall, the Niobe Remote Magnetic Navigation System has been utilized in nearly 23,000 cases worldwide. These include ablations of a wide variety of cardiac arrhythmias in all four chambers of the heart and across a broad spectrum of patients ranging from pediatric to geriatric. Included in the Niobe clinical experience are several very compelling procedures in patients with congenital heart defects and patients with peripheral vascular occlusive disease.

The Odyssey portfolio of products provides an innovative information backbone for managing, controlling, recording and sharing procedures performed in interventional labs. The Odyssey Workstation standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, the Odyssey enables the sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Connect providing a forum for defining clinical best practices across a broad spectrum of medical procedures.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis System have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward-Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Names Daniel Johnston as Chief Financial Officer
2. Stereotaxis Reports 19% Second Quarter Revenue Growth
3. Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call
4. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2009
5. Stereotaxis Reports First Quarter 2009 Financial Results
6. Stereotaxis Announces First Quarter 2009 Earnings Release Date and Conference Call
7. Stereotaxis Extends Its Credit Facility With Silicon Valley Bank
8. Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers
9. Stereotaxis Announces First Uses of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
10. Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
11. Stereotaxis Reports Fourth Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) ... Daniel A. Potter -- are proud of the recent release of their 2014 in ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 Acquisition Expands ... Product Development Capabilities in North America ... . Indegene ( http://www.indegene.com ), ... acquisition of Skura Corporation,s life science business. Skura,s ... sales enablement technology for life science organizations and ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
Breaking Medicine Technology: